Kinnevik Investment


12/08/20 -"Our estimated NAV sees a SEK13.6 per share increase on the back of the increased valuation on Kinnevik's unlisted assets, particularly those involved in the healthcare sector (Babylon) and the ..."

Pages
62
Language
English
Published on
12/08/20
You may also be interested by these reports :
19/04/24
Investor has delivered a remarkable start to the year through impressive performances in all segments, driving a 10% increase in its NAV – ...

18/04/24
EdenRed’s Q1 2024 update was ahead of the consensus and our estimates. Organic growth increased by 16.9% on a lfl basis, driven by growth across all ...

18/04/24
Kinnevik released lacklustre results as its growth-oriented portfolio continued to suffer in this high interest rate environment. However, the new ...

16/04/24
Wise released its trading update for the Q4 24, revealing a continuation of the trend observed in the previous quarters. NII surpassed the compiled ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO